Research programme: AOC3 protein antagonists - La Jolla Pharmaceutical

Drug Profile

Research programme: AOC3 protein antagonists - La Jolla Pharmaceutical

Alternative Names: LJP-1207; LJP-1586

Latest Information Update: 06 Mar 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Benzylamines; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Inflammation; Multiple sclerosis; Rheumatoid arthritis; Stroke; Ulcerative colitis

Most Recent Events

  • 06 Mar 2013 Discontinued - Preclinical for Autoimmune disorders in USA (PO) before 2013
  • 06 Mar 2013 Discontinued - Preclinical for Inflammation in USA (PO) before 2013
  • 06 Mar 2013 Discontinued - Preclinical for Multiple sclerosis in USA (PO) before 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top